A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy, Safety, and Tolerability of Cannabidiol Oral Solution for the Treatment of Subjects With Prader-Willi Syndrome

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy, Safety, and Tolerability of Cannabidiol Oral Solution for the Treatment of Subjects With Prader-Willi Syndrome

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Dec 2017

At a glance

  • Drugs Cannabidiol (Primary)
  • Indications Prader-Willi syndrome
  • Focus Therapeutic Use
  • Sponsors INSYS Therapeutics, Inc
  • Most Recent Events

    • 01 Dec 2017 Planned End Date changed from 1 Dec 2017 to 1 Jan 2018.
    • 01 Dec 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Jan 2018.
    • 01 Dec 2017 Planned initiation date changed from 30 Nov 2017 to 30 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top